THOR contributed to cancer progression by interacting with IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1); conversely, THOR silencing in cSCC cells induced the downregulation of IGF2BP1 mRNA and the inhibition of tumor progression [52]. Here, THORLNC is linked to cancer.